

April 2024

PATIENT DERIVED, PATIENT INSPIRED

FINDING NEW TARGETS TO FIGHT CANCER



OVERVIEW



- A pre-clinical stage R&D Immune-oncology company
- Exploiting our unique platform to identify new Immune check points
- Our lead, anti-4CB1 is a novel fully human, first-in-class anti-HVEM mAb
- Anti-4CB1 in-vivo efficacy studies demonstrated promising results as monotherapy and in combination with the gold standard anti-PD1

BY THE NUMBERS

\$17M+ In funding raised to date

Grant Recipients


SUPPORTED BY רשות החדשנות Israel Innovation Authority




IMMUNE CHECKPOINT INHIBITOR (ICI) RESEARCH HAD A HUGE PROMISE...

Leading to great results after first FDA approval in 2011





















After billions of dollars, and years of development

ONLY 3 ICI DRUG CATEGORIES APPROVED - A HUGE DISAPPOINTMENT






4C BIOMED IS HERE TO UNLOCK THE PROMISE OF IMMUNE CHECKPOINT INHIBITORS

TO SUCCESSFULLY FIND A WORLD OF NEW TARGETS




OUR APPROACH

A bottom-up approach






OUR DIFFERENTIATION **EX-VIVO MODEL**




Surgical resection of tumor






OUR DIFFERENTIATION **EX-VIVO MODEL**





EX-VIVO MODEL







AND IT WORKS THE RESULTS SPEAK FOR THEMSELVES



Reached clinical trials by Pharma companies

Of discovered target categories (IIA-supported research)



Less Noise

Compared to similar siRNA screenings (average noise of 7%)




ANTI-HVEM (ANTI-4CB1) VS. ANTI-LAG-3 (BMS) ANTI TUMOR ACTIVITY IN MC38 COLON CARCINOMA MODEL

	Monotherapy		Combination with anti-PD1	
	Anti-4CB1	Anti-LAG-3 (BMS)	Anti-4CB1	Anti-LAG-3 (BMS)
Tumor Growth Inhibition (%)	50	-	96	70
Tumor-free mice (%)	-	-	20	-



EX VIVO: PATIENT DERIVED USING OUR ANTIBODY ON FRESH PATIENT TISSUE SAMPLES

>30 SETS \ YEAR Autologous sets for screening





Indication	Anti-4CB1	Anti-PD1	Combination	
Endometrial	2.1		1.9	
Hepatocellular	2.4		N/T	
Melanoma	1.6		1.7	
Melanoma	1.7		2.0	
Colon	1.3			
Ovarian	1.5		1.5	
Renal	1.4			
Renal	1.2		N/T	
Endometrial	3.3	2.5	3.2	
Hepatocellular	1.7	1.7	2.6	
Melanoma	1.7	1.8	1.8	
Colon	1.3	1.2	1.2	
Colon	1.2	1.1	1.5	
Renal	1.6	1.5	1.7	
Small bowel	1.2	1.3	N/T	
Endometrial		1.4		
Renal		1.3		
Soft tissue		1.5	1.7	
Bladder		1.2		



Ex-vivo sample responded to Anti-HVEM and Anti-PD1 monotherapy

Ex-vivo sample responded to Anti-PD1 monotherapy

Green -above 10% increase in killing (figures represent fold change above isotype control treatment) and p-value ≤0.08 Red - below 10% increase in killing (above isotype control treatment) or p-value ≥0.08 N/T - not tested







X2 MORE EFFECTIVE VS GOLD STANDARD (ANTI-PD1)



ACBIOMED IMPROVING THE GOLD STANDARD



EMPIRICAL EVIDENCE

AS MONOTHERAPY

UP TO

53% Tumor growth inhibition

IN COMBINATION WITH GOLD STANDARD

96%

Tumor growth inhibition

20% Total

eradication

X2

Increase in Survival



EMPIRICAL EVIDENCE

AS MONOTHERAPY

UP TO

53% Tumor growth inhibition

IN COMBINATION WITH GOLD STANDARD

96%

Tumor growth inhibition 20% Total eradication **X2**

Increase in Survival

X2 More Effective Ex-Vivo

Ex-Vivo Our lead works on X2 more patient samples than anti-PD1



4C BIOMED TIMELINE

Positive Pre IND FDA response - clearing the path to clinical trials

Fund-raising (Series A) towards clinical development of our lead Anti-4CB1

Cell line and Process development completed

GLP toxicity study in cynomolgus (4-week repeated-dose) is planned to Q3 2024

First Phase-I clinical trial is expected during Q3 2025



4C BIOMED



MR. ANTHONY L. ANGEL CHAIRMAN



DR. EYAL GREENBERG, PHD, MBA CHIEF EXECUTIVE OFFICER



DR. GILLI GALORE-HASKEL, PHD VP R&D

DR. EFRAT MERHAVI-SHOHAM, PHD HEAD OF RESEARCH



PROF. GAL MARKEL, MD, PHD, MBA CHIEF SCIENTIFIC OFFICER



DR. DORIT LANDSTEIN, PHD HEAD OF CMC



PROF. JACOB SCHACHTER, MD CHIEF MEDICAL OFFICER



OVERVIEW



- A pre-clinical stage R&D Immune-oncology company
- Exploiting our unique platform to identify new Immune check points
- Our lead, anti-4CB1 is a novel fully human, first-in-class anti-HVEM mAb
- Anti-4CB1 in-vivo efficacy studies demonstrated promising results as monotherapy and in combination with the gold standard anti-PD1

BY THE NUMBERS

\$17M+ In funding raised to date

Grant Recipients

SUPPORTED BY רשות החדשנות Israel Innovation Authority



LET'S GET TO WORK EYAL@4CBIOMED.COM



LET'S GET TO WORK EYAL@4CBIOMED.COM

